Here in Indonesia, there are tremendous unmet medical needs within a vast population which we at MSD hope to help address through our innovative medicines and vaccines.The five key therapeutic areas we are focused upon in the region are also very relevant to Indonesia: cardiovascular, diabetes, infectious disease, vaccines, and women's health.The Indonesian government has a far-ranging vision to increase access to healthcare for more Indonesians, with the ultimate aim of universal health coverage. At MSD, we look forward to engaging in a constructive dialogue with the government, as well as healthcare professionals, key opinion leaders, payers, and patient groups to determine how we each play our part and collectively contribute to attainment of this goal.In Indonesia, MSD operates three legal entities: PT MSD Indonesia, PT Merck Sharp Dohme Pharma Tbk., and PT Intervet Indonesia. Headquartered in Jakarta, with more than 500 employees, we offer a wide range of medicines for human and animal health. Human health products are all ethical/prescription medicines in therapeutic areas such as cardiovascular, diabetes, pain, vaccines, women's health, hepatology, oncology, repiratory, and dermatology. While animal health products consist of vaccines, anti bacteria, and reproductive hormones.MSD in Indonesia established its business when two leading pharmaceutical companies, Schering Plough and Merck & Co.Inc undertook joint operation in 2009. Previously in 2007, Schering Plough Corporation had acquaired Organon BioScience. Actually MSD products were present when they started commercialized trough distributor at 1990s.Our production facilities are located at Pandaan, East Java. It comprises of manufacturing and packaging facilities. We manufacture a wide array of creams, ointments, liquids, solutions and tablets for dermatological application, as well as cough expectorants and nasal sprays.The packaging facility launched in 2012 will serve supply and distribution to Indonesia, Asia and other parts of the world. Products to be packaged in this new plant include medicines for infectious, cardiovascular and respiratory diseases, as well as oncology, diabetes and hypertension.Built at an investment of US$21 million, this new plant is not just to build a facilitiy, but also represent a commitment to invest in the Indonesian workforce and people development.
Here in Indonesia, there are tremendous unmet medical needs within a vast population which we at MSD hope to help address through our innovative medicines and vaccines.The five key therapeutic areas we are focused upon in the region are also very relevant to Indonesia: cardiovascular, diabetes, infectious disease, vaccines, and women's health.The Indonesian government has a far-ranging vision to increase access to healthcare for more Indonesians, with the ultimate aim of universal health coverage. At MSD, we look forward to engaging in a constructive dialogue with the government, as well as healthcare professionals, key opinion leaders, payers, and patient groups to determine how we each play our part and collectively contribute to attainment of this goal.In Indonesia, MSD operates three legal entities: PT MSD Indonesia, PT Merck Sharp Dohme Pharma Tbk., and PT Intervet Indonesia. Headquartered in Jakarta, with more than 500 employees, we offer a wide range of medicines for human and animal health. Human health products are all ethical/prescription medicines in therapeutic areas such as cardiovascular, diabetes, pain, vaccines, women's health, hepatology, oncology, repiratory, and dermatology. While animal health products consist of vaccines, anti bacteria, and reproductive hormones.MSD in Indonesia established its business when two leading pharmaceutical companies, Schering Plough and Merck & Co.Inc undertook joint operation in 2009. Previously in 2007, Schering Plough Corporation had acquaired Organon BioScience. Actually MSD products were present when they started commercialized trough distributor at 1990s.Our production facilities are located at Pandaan, East Java. It comprises of manufacturing and packaging facilities. We manufacture a wide array of creams, ointments, liquids, solutions and tablets for dermatological application, as well as cough expectorants and nasal sprays.The packaging facility launched in 2012 will serve supply and distribution to Indonesia, Asia and other parts of the world. Products to be packaged in this new plant include medicines for infectious, cardiovascular and respiratory diseases, as well as oncology, diabetes and hypertension.Built at an investment of US$21 million, this new plant is not just to build a facilitiy, but also represent a commitment to invest in the Indonesian workforce and people development.
Here in Indonesia, there are tremendous unmet medical needs within a vast population which we at MSD hope to help address through our innovative medicines and vaccines.The five key therapeutic areas we are focused upon in the region are also very relevant to Indonesia: cardiovascular, diabetes, infectious disease, vaccines, and women's health.The Indonesian government has a far-ranging vision to increase access to healthcare for more Indonesians, with the ultimate aim of universal health coverage. At MSD, we look forward to engaging in a constructive dialogue with the government, as well as healthcare professionals, key opinion leaders, payers, and patient groups to determine how we each play our part and collectively contribute to attainment of this goal.In Indonesia, MSD operates three legal entities: PT MSD Indonesia, PT Merck Sharp Dohme Pharma Tbk., and PT Intervet Indonesia. Headquartered in Jakarta, with more than 500 employees, we offer a wide range of medicines for human and animal health. Human health products are all ethical/prescription medicines in therapeutic areas such as cardiovascular, diabetes, pain, vaccines, women's health, hepatology, oncology, repiratory, and dermatology. While animal health products consist of vaccines, anti bacteria, and reproductive hormones.MSD in Indonesia established its business when two leading pharmaceutical companies, Schering Plough and Merck & Co.Inc undertook joint operation in 2009. Previously in 2007, Schering Plough Corporation had acquaired Organon BioScience. Actually MSD products were present when they started commercialized trough distributor at 1990s.Our production facilities are located at Pandaan, East Java. It comprises of manufacturing and packaging facilities. We manufacture a wide array of creams, ointments, liquids, solutions and tablets for dermatological application, as well as cough expectorants and nasal sprays.The packaging facility launched in 2012 will serve supply and distribution to Indonesia, Asia and other parts of the world. Products to be packaged in this new plant include medicines for infectious, cardiovascular and respiratory diseases, as well as oncology, diabetes and hypertension.Built at an investment of US$21 million, this new plant is not just to build a facilitiy, but also represent a commitment to invest in the Indonesian workforce and people development.